Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.91 |
| ▸ | CCR5 | P51681 | 12/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053063 | 1.00 | KCNH2 (0.91) | KCNH2CCR5 | |
| SCHEMBL30227462 | 1.00 | KCNH2 (0.91) | KCNH2CCR5 | |
| SCHEMBL1198749 | 0.95 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL1080663 | 0.95 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL30227220 | 0.95 | KCNH2 (1.00) | KCNH2CCR5 | |
| Water SCHEMBL4012865 | 0.94 | KCNH2 (0.99) | KCNH2CCR5 | |
| SCHEMBL13719481 | 0.94 | CCR5 (0.91) | KCNH2CCR5 | |
| Water SCHEMBL4012863 | 0.94 | KCNH2 (0.99) | KCNH2CCR5 | |
| SCHEMBL3070604 | 0.93 | KCNH2 (1.00) | KCNH2CCR5 | |
| SCHEMBL3070606 | 0.93 | KCNH2 (1.00) | KCNH2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2741777-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-01-18 | — | — | EP | claimed |
| US-20130039885-A1 | LEUKOTOXIN E/D AS A NEW ANTI-INFLAMMATORY AGENT AND MICROBICIDE | NEW YORK UNIVERSITY (US) | 2013-02-14 | — | — | US | claimed |
| EP-2552429-A1 | COMBINATION THERAPY COMPRISING A CCR5 ANTAGONIST, A HIV-1 PROTEASE INHIBITOR AND A PHARMACOKINETIC ENHANCER | Phivco-1 LLC (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011121558-A1 | COMBINATION THERAPY COMPRISING A CCR5 ANTAGONIST, A HIV-1 PROTEASE INHIBITOR AND A PHARMACOKINETIC ENHANCER | PHIVCO-1 LLC (US) | 2011-10-06 | — | — | WO | claimed |
| EP-1937639-B1 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | claimed |
| US-20090247570-A1 | PHARMACEUTICALS | PFIZER INC | 2009-10-01 | — | — | US | claimed |
| US-9950062-B2 | Compounds and compositions as TLR activity modulators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-04-24 | — | — | US | disclosed |
| EP-2473508-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-9365506-B2 | Compounds and compositions as TLR2 agonists | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-9045470-B2 | Compounds and compositions as TLR activity modulators | IRM LLC (BM) | 2015-06-02 | — | — | US | disclosed |
| EP-2268618-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-05-27 | — | — | EP | disclosed |
| US-8895577-B2 | Compounds and compositions as TLR activity modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-11-25 | — | — | US | disclosed |
| US-20070185157-A1 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
| US-7217721-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217721-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| WO-2007034312-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| EP-1740550-A1 | SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREAMENT OF HIV | Pfizer Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006077499-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005100322-A1 | SULPHUR-LINKED IMIDAZOLE COMPOUNDS FOR THE TREAMENT OF HIV | PFIZER LIMITED (GB) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225432-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR1, TLR6, TLR7 | KCNH2 4580/4885CCR5 352/4885 |
| US-20070185157-A1 | Tropane derivatives useful in therapy | CCR5, CXCR4, CX3CR1 | KCNH2 3530/4885CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.